Evidence map›Paper›PMID 33782012›Full record

ArticleAntimicrobial agents and chemotherapy2021

Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor.

Li Wang, Qihui Zhu, Kunlun Xiang, Yaling Zhang, Baocun Li, Xin Yu, Guang Yang, Chungen Liang, Hongying Yun, Meifang Zhang and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Li Wang *Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China vlwang00@163.com goodlucksept2016@yahoo.com.ORCID 0000-0001-9580-2476
Qihui Zhu *Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Kunlun XiangInfectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Yaling ZhangInfectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Baocun LiInfectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Xin YuInfectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Guang YangInfectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Chungen LiangMedicinal Chemistry, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Hongying YunMedicinal Chemistry, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Meifang ZhangLead Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Ning QinLead Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Lu GaoInfectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China vlwang00@163.com goodlucksept2016@yahoo.com.
Roche (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A high-throughput screen of a Roche internal chemical library based on inhibition of the respiratory syncytial virus (RSV)-induced cytopathic effect (CPE) on HEp-2 cells was performed to identify RSV inhibitors. Over 2,000 hits were identified and confirmed to be efficacious against RSV infection

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsHumansVaccinia virusViral ProteinsVirus ReplicationViral Proteinsinhibitorreplicationrespiratory syncytial virus

Identifiers

PMID33782012
PMCPMC8316115
OpenAlexW3147839217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.